Trademark: 90700876
Status Date
Tuesday, February 13, 2024
Registration Number
7305215
Registration Date
Tuesday, February 13, 2024
Filing Date
Monday, May 10, 2021
Published for Opposition
Tuesday, July 26, 2022
5 Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for prevention of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for detection of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for localization of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for human use that trigger expression or activation in the human body of a biomarker, compound or body response useable for therapy of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for prevention of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for detection of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for localization of diseases, namely, cancer or other diseases related to genetic dysregulation; Medical products for animal use that trigger expression or activation in the animal body of a biomarker, compound or body response useable for therapy of diseases, namely, cancer or other diseases related to genetic dysregulation
44 Medical services for prevention of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for detection of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for localization of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for therapy of diseases in humans based on technology focused on triggering the expression or activation in the human body of a biomarker, compound or body response usable for these medical services; Medical services for prevention of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for detection of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for localization of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services; Medical services for therapy of diseases in animals based on technology focused on triggering the expression or activation in the animal body of a biomarker, compound or body response usable for these medical services
Feb 13, 2024
Notice Of Registration Confirmation Emailed
Feb 13, 2024
Registered-Principal Register
Jan 10, 2024
Notice Of Acceptance Of Statement Of Use E-Mailed
Jan 9, 2024
Allowed Principal Register - Sou Accepted
Jan 9, 2024
Teas/Email Correspondence Entered
Jan 9, 2024
Correspondence Received In Law Office
Jan 9, 2024
Assigned To Lie
Aug 15, 2023
Teas Response To Office Action Received
Jul 7, 2023
Application Extension Granted/Receipt Provided
Jul 7, 2023
Application Extension To Response Period - Received
Apr 10, 2023
Notification Of Non-Final Action E-Mailed
Apr 10, 2023
Non-Final Action E-Mailed
Apr 10, 2023
Su - Non-Final Action - Written
Feb 24, 2023
Statement Of Use Processing Complete
Feb 1, 2023
Use Amendment Filed
Feb 23, 2023
Case Assigned To Intent To Use Paralegal
Feb 1, 2023
Teas Statement Of Use Received
Sep 20, 2022
Noa E-Mailed - Sou Required From Applicant
Jul 26, 2022
Official Gazette Publication Confirmation E-Mailed
Jul 26, 2022
Published For Opposition
Jul 6, 2022
Notification Of Notice Of Publication E-Mailed
Jun 23, 2022
Approved For Pub - Principal Register
May 27, 2022
Teas/Email Correspondence Entered
May 24, 2022
Correspondence Received In Law Office
May 24, 2022
Teas Response To Office Action Received
Jan 19, 2022
Notification Of Non-Final Action E-Mailed
Jan 19, 2022
Non-Final Action E-Mailed
Jan 19, 2022
Non-Final Action Written
Jan 13, 2022
Assigned To Examiner
Aug 10, 2021
New Application Office Supplied Data Entered
May 13, 2021
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
